The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes

European Journal of Clinical Investigation

Volumn 32, Issue SUPPL. 3, 2002, Pages 35-45

  Bergman, Richard N ^a,d   Finegood, D T ^b   Kahn, S E ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biological models; Disease progression; Insulin resistance; Islets of Langerhans physiopathology; Noninsulin dependent diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID; INSULIN;

B LYMPHOCYTE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; DISEASE COURSE; METABOLISM; PANCREAS ISLET; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

AMYLOID; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; RISK FACTORS;

EID: 0036615275     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1046/j.1365-2362.32.s3.5.x     Document Type: Review

References (117)

1. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988-92.
2. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19:491-503.
3. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990;113:909-15.
4. Martin BC, Warram JH, Rosner B, Rich SS, Soeldner JS, Krolewski AS. Familial clustering of insulin sensitivity. Diabetes 1992;41:850-4.
5. Kahn SE. Clinical review 135. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-58.
6. Kahn SE. Regulation of β-cell function in vivo: from health to disease. Diabetes Rev 1996;4:372-89.
7. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity and demography. Diabetes Care 1995;18:1050-64.
8. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68.
9. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.
10. Gerich JE. Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology. Eur J Clin Invest 2002;32 (Suppl. 3):46-53.
11. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 1995;44:173-9.
12. Mykkanen L, Haffher SM, Kuusisto J, Pyorala K, Hales CN, Laakso M. Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Diabetologia 1995;38:1176-82.
13. O'Meara NM, Sturis J, Van Cauter E, Polonsky KS. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest 1993;92:262-71.
14. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985;4:110-25.
15. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999;48:241-53.
16. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
17. Andres R, Swerdloff R, Pozefsky T, Coleman D. Manual feedback technique for the control of blood glucose concentration. In: Automation, in Analytical Chemistry Skeggs LT (ed.). New York: Mediad; 1966, pp. 486-91.
18. Sherwin RS, Kramer KJ, Tobin JD, Insel PA, Liljenquist JE, Berman M et al. A model of the kinetics of insulin in man. J Clin Invest 1974;53:1481-92.
19. Insel PA, Liljenquist JE, Tobin JD, Shenvin RS, Watkins P, Andres R et al. Insulin control of glucose metabolism in man. J Clin Invest 1975;55:1057-66.
20. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
21. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981;30:387-92.
22. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667-E677.
23. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man. measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456-67.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
25. Grulet H, Durlach V, Hecart AC, Gross A, Leutenegger M. Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index. Diabetes Res Clin Pract 1993;20:201-7.
26. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987;79:790-800.
27. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942-7.
28. Kruszynska YT, Harry DS, Bergman RN, McIntyre N. Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia 1993;36:121-8.
29. Swan JW, Walton C, Godsland IF. Assessment of insulin sensitivity in man: a comparison of minimal model- and euglycaemic clamp-derived measures in health and heart failure. Clin Sci (Colch) 1994;86:317-22.
30. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen YD et al. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes 1994;43:1114-21.
31. Korytkowski MT, Berga SL, Horwitz MJ. Comparison of the minimal model and the hyperglycemic clamp for measuring insulin sensitivity and acute insulin response to glucose. Metabolism 1995;44:1121-5.
32. Pacini G, Finegood DT, Bergman RN. A minimal-model-based glucose clamp yielding insulin sensitivity independent of glycemia. Diabetes 1982;31:432-41.
33. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999;22:818-22.
34. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
35. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001;24:362-5.
36. Zaccaro DJ, Bergman RN, Watanabe RM, Haffner SM, Saad MF, Norris JM et al. Insulin sensitivity per se has genetic basis distinct from surrogate measures based on fasting insulin and glucose. Diabetes 2001;50 (Suppl. 2):A75.
37. Lerner RL, Porte DJ. Acute and steady-state insulin responses to glucose in nonobese diabetic subjects. J Clin Invest 1972,51:1624-31.
38. Licko V, Silvers A. Open-loop glucose-insulin control with threshold secretory mechanism: analysis of intravenous glucose tolerance tests in man. Math Biosci 1975;27:319-32.
39. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 1980;51:520-8.
40. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 1986;77:98-105.
41. Volund A, Polonsky KS, Bergman RN. Calculated pattern of intraportal insulin appearance without independent assessment of C-peptide kinetics. Diabetes 1987;36:1195-202.
42. Watanabe RM, Steil GM, Bergman RN. Critical evaluation of the combined model approach for estimation of prehepatic insulin secretion. Am J Physiol 1998;274:E172-E183.
43. Watanabe RM, Bergman RN. Accurate measurement of endogenous insulin secretion does not require separate assessment of C-peptide kinetics. Diabetes 2000;49:373-82.
44. Kjems LL, Christiansen E, Volund A, Bergman RN, Madsbad S. Validation of methods for measurement of insulin secretion in humans in vivo. Diabetes 2000;49:580-8.
45. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-72.
46. 6 Buchanan TA, Metzger BE, Freinkel N, Bergman RN. Insulin sensitivity and β-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 1990;162:1008-14.
47. Kahn SE, Larson VG, Beard JC, Cain KC, Fellingham GW, Schwartz RS et al. Effect of exercise on insulin action, glucose tolerance, and insulin secretion in aging. Am J Physiol 1990;258:E937-E943.
48. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995;96:520-7.
49. Ryan EA, Imes S, Liu D, McManus R, Finegood DT, Polonsky KS et al. Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes 1995;44:506-12.
50. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997;100:530-7.
51. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299-306.
52. Johnston C, Ward WK, Beard JC, McKnight B, Porte DJ. Islet function and insulin sensitivity in the non-diabetic offspring of conjugal type 2 diabetic patients. Diabet Med 1990;7:119-25.
53. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE. Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 1999;84:1398-403.
54. Watanabe RM, Valle T, Hauser ER, Ghosh S, Eriksson J, Kohtamaki K et al. Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. Hum Hered 1999;49:159-68.
55. Hanis CL, Boerwinkle E, Chakraborty R, Ellsworth DL, Concannon P, Stirling B et al. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 1996;13:161-6.
56. Mahtani MM, Widen E, Lehto M, Thomas J, McCarthy M, Brayer J et al. Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nat Genet 1996;14:90-4.
57. Hanson RL, Ehm MG, Pertitt DJ, Prochazka M, Thompson DB, Timberlake D et al. An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet 1998;63:1130-8.
58. Duggirala R, Blangero J, Almasy L, Dyer TD, Williams KL, Leach RJ et al. Linkage of type 2 diabetes mellitus and of age at onset to a genetic location on chromosome 10q in Mexican Americans. Am J Hum Genet 1999;64:1127-40.
59. Elbein SC, Hoffman MD, Teng K, Leppert MF, Hasstedt SJ. A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians. Diabetes 1999;48:1175-82.
60. Ehm MG, Karnoub MC, Sakul H, Gottschalk K, Holt DC, Weber JL et al. Genomevvide search for type 2 diabetes susceptibility genes in four American populations. Am J Hum Genet 2000;66:1871-81.
61. Ghosh S, Watanabe RM, Hauser ER, Valle T, Magnuson VL, Erdos MR et al. Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. Proc Natl Acad Sci USA 1999;96:2198-203.
62. Ghosh S, Watanabe RM, Valle TT, Hauser ER, Magnuson VL, Langefeld CD et al. The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 2000;67:1174-85.
63. Watanabe RM, Ghosh S, Langefeld CD, Valle TT, Hauser ER, Magnuson VL et al. The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. II. An autosomal genome scan for diabetes-related quantitative-trait loci. Am J Hum Genet 2000;67:1186-200.
64. Finegood DT, Topp B. β-cell deterioration - prospects for reversal or prevention. Diabetes Obes Metab 2001;3 (Suppl. 1):S20-S27.
65. Ward WK, Johnston CL, Beard JC, Benedetti TJ, Halter JB, Porte DJ. Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 1985;34:861-9.
66. Homko C, Sivan E, Chen X, Reece EA, Boden G. Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab 2001;86:568-73.
67. Buchanan TA. Pancreatic B-cell defects in gestational diabetes, implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 2001;86:989-93.
68. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest 2002;32 (Suppl. 3):14-23.
69. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002;32 (Suppl. 3):24-35.
70. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998;391:900-4.
71. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000;26:163-75.
72. Bergman RN, van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP et al. Central role of the adipocyte in the metabolic syndrome. J Invest Med 2001;49:119-26.
73. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19:477-90.
74. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967;46:1954-62.
75. Pfeifer MA, Halter JB, Porte DJ. Insulin secretion in diabetes mellitus. Am J Med 1981;70:579-88.
76. Simon C, Brandenberger G, Follenius M. Ultradian oscillations of plasma glucose, insulin, and C-peptide in man during continuous enteral nutrition. J Clin Endocrinol Metab 1987;64:669-74.
77. Shapiro ET, Tillil H, Polonsky KS, Fang VS, Rubenstein AH, Van Cauter E. Oscillations in insulin secretion during constant glucose infusion in normal man: relationship to changes in plasma glucose. J Clin Endocrinol Metab 1988;67:307-14.
78. Sturis J, Van Cauter E, Blackman JD, Polonsky KS. Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. J Clin Invest 1991;87:439-45.
79. + channels and insulin secretion, their role in health and disease. Diabetologia 1999;42:903-19.
80. Wolffenbuttel BH, Graal MB. New treatments for patients with type 2 diabetes mellitus. Postgrad Med J 1996;72:657-62.
81. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998;273:3547-50.
82. Halban PA. Structural domains and molecular lifestyles of insulin and its precursors in the pancreatic beta cell. Diabetologia 1991;34:767-78.
83. Neerman-Arbez M, Cirulli V, Halban PA. Levels of the conversion endoproteases PC1 (PC3) and PC2 distinguish between insulin-producing pancreatic islet beta cells and non-beta cells. Biochem J 1994;300:57-61.
84. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte DJ. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987;30:698-702.
85. Duckworth WC, Kitabchi AE. Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med 1972;53:418-27.
86. Gorden P, Hendricks CM, Roth J. Circulating proinsulin-like component in man: increased proportion in hypoinsulinemic states. Diabetologia 1974;10:469-74.
87. Mako ME, Starr JI, Rubenstein AH. Circulating proinsulin in patients with maturity onset diabetes. Am J Med 1977;63:865-9.
88. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW et al. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1990;70:1247-53.
89. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997;46:1725-32.
90. Skelly RH, Bollheimer LC, Wicksteed BL, Corkey BE, Rhodes CJ. A distinct difference in the metabolic stimulus-response coupling pathways for regulating proinsulin biosynthesis and insulin secretion that lies at the level of a requirement for fatty acyl moieties. Biochem J 1998;331 (2):553-61.
91. Furukawa H, Carroll RJ, Swift HH, Steiner DF. Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic beta-cell line MIN6. Diabetes 1999;48:1395-401.
92. Prigeon RL, Jacobson RK, Porte DJ, Kahn SE. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:3295-8.
93. Prigeon RL, Kahn SE, Porte DJ. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998;83:819-23.
94. Kahn S, Freed MI, Porter LE, Jones NP. Proinsulin/insulin ratio reduced and β-cell function improved in type 2 diabetes with rosiglitazone. Diabetes Res Clin Pract 2000;50 (Suppl. 1):S62-S63.
95. Sempoux C, Guiot Y, Dubois D, Moulin P, Rahier J. Human type 2 diabetes: morphological evidence for abnormal beta-cell function. Diabetes 2001;50 (Suppl. 1):S172-S177.
96. de Koning EJ, Bodkin NL, Hansen BC, Clark A. Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia 1993;36:378-84.
97. Finegood DT, McArthur MD, Kojwang D, Thomas D, Topp B, Leonard T et al. Beta-cell mass dynamics in zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50:1021-9.
98. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998;47:358-64.
99. Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 1995;44:249-56.
100. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis. a link between obesity and diabetes. Proc Natl Acad Sci USA 1998;95:2498-502.
101. Lee Y, Hirose H, Zhou YT, Esser V, McGarry JD, Unger RH. Increased lipogenic capacity of the islets of obese rats a role in the pathogenesis of NIDDM. Diabetes 1997;46:408-13.
102. Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001;50 (Suppl. 1):S118-S121.
103. Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 2001;50:1771-7.
104. Topp B, Promislow K, Devries G, Miura RM, Finegood DT. A model of beta-cell mass, insulin, and glucose kinetics: Pathways to diabetes. J Theor Biol 2000;206:605-19.
105. Bell ET. Hyalinization of the islets of Langerhans in nondiabetic individuals. Am J Pathol 1959;35:801-5.
106. Westermark P. Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 1972;77:91-4.
107. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH et al. Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 1990;33:285-9.
108. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG et al. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 1996;93:3492-6.
109. Smith S, Boam DS, Cawthorne MA, Sidaway J, Newman M, Wilkinson M et al. Rosiglitazone improves insulin sensitivity and reduces hyperexpression of insulin and amylin mRNAs in pancreatic islets. Diabetes 1998;47 (Suppl. 1):A94.
110. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:176-85.
111. Carey DG, Cowin GJ, Galloway GJ, Dodrell D, Richards J, Jones NP. Rosiglitazone increases insulin sensitivity and reduces factors associated with insulin resistance in type 2 diabetics. Diabetes Res Clin Pract 2000;50 (Suppl. 1):S64.
112. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8.
113. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000;2:363-72.
114. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998;19:217-31.
115. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J et al. Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone. Diabetes 2001;50 (Suppl. 2):A81.
116. Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 1990;71:1508-18.
117. Kahn SE, Prigeon RL, Schwartz RS, Fujimoto WY, Knopp RH, Brunzell JD et al. Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity. J Nutr 2001;131:354S-60S.